Evidence map›Paper›PMID 39802106›Full record

ArticleEndoscopic ultrasound

A prospective comparative trial to determine the optimal number of EUS-guided fineneedle passes for successful organoid creation in pancreatic ductal adenocarcinoma.

Pradermchai Kongkam, Kittithat Tantitanawat, May Sirikalyanpaiboon, Praewphan Ingrungruanglert, Thanikan Sukaram, Pobsook Tawainak, Thanawat Luangsukrerk, Wiriyaporn Ridtitid, Rungsun Rerknimitr, Nipan Israsena

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endoscopic ultrasound. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Pradermchai KongkamDivision of Hospital and Ambulatory Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.ORCID https://orcid.org/0000-0001-5798-9217
Kittithat TantitanawatDivision of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
May SirikalyanpaiboonDepartment of medicine, School of Medicine, Mae Fah Luang University, Chiang Rai, Thailand.
Praewphan IngrungruanglertCenter of Excellence for Stem Cell and Cell Therapy, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Thanikan SukaramDivision of Hospital and Ambulatory Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Pobsook TawainakDivision of Hospital and Ambulatory Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Thanawat LuangsukrerkDivision of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Wiriyaporn RidtitidDivision of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Rungsun RerknimitrDivision of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Nipan IsrasenaCenter of Excellence for Stem Cell and Cell Therapy, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: EUS-guided fine-needle organoid creation (EUS-FNO) from pancreatic cancer (PC) has been increasingly important for precision medicine. The cost for pancreatic organoid creation is substantial and close to 2000 USD/specimen in our institution, and the specimen has to be processed immediately after tissue acquisition so the more passes and specimens, the higher cost of organoid creation will incur. To date, no prospective comparison trial has answered how many needle passes of EUS-FNO needed for a successful organoid creation. Methods: A prospective trial comparing the success rate of EUS-FNO between the first-pass (group A) Results: Fifty-two patients (33 females, 19 males) with PC underwent EUS-FNO during the period from September 15, 2020, to February 28, 2022, were recruited. Median age (range) was 64.0 (46-88) years. Median BMI (range) was 20.0 (14.6-30.8) kg/m Conclusion: Results from this current prospective trial showed that a single pass of EUS-FNO from a PC by using a 20-G forward-bevel needle provided a high success rate. Adding the second pass did not increase the success rate of EUS-FNO.

Indexed as

EUSFine needle biopsyPancreatic cancer organoid

Identifiers

PMID39802106
PMCPMC11723681

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.